Zynerba Pharmaceuticals Probability of Future Stock Price Finishing Over 0.3
| ZYNEDelisted Stock | USD 0.36 0.01 2.70% |
Zynerba |
Zynerba Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Zynerba Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Zynerba Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Zynerba Pharmaceuticals is not yet fully synchronised with the market data | |
| Zynerba Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Zynerba Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (35.04 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Zynerba Pharmaceuticals currently holds about 62.49 M in cash with (23.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.44, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Zynerba Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Zynerba Stock often depends not only on the future outlook of the current and potential Zynerba Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Zynerba Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 42.7 M | |
| Cash And Short Term Investments | 50.6 M |
Zynerba Pharmaceuticals Technical Analysis
Zynerba Pharmaceuticals' future price can be derived by breaking down and analyzing its technical indicators over time. Zynerba Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Zynerba Pharmaceuticals. In general, you should focus on analyzing Zynerba Stock price patterns and their correlations with different microeconomic environments and drivers.
Zynerba Pharmaceuticals Predictive Forecast Models
Zynerba Pharmaceuticals' time-series forecasting models is one of many Zynerba Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Zynerba Pharmaceuticals' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Zynerba Pharmaceuticals
Checking the ongoing alerts about Zynerba Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Zynerba Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Zynerba Pharmaceuticals is not yet fully synchronised with the market data | |
| Zynerba Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Zynerba Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (35.04 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Zynerba Pharmaceuticals currently holds about 62.49 M in cash with (23.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.44, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Other Consideration for investing in Zynerba Stock
If you are still planning to invest in Zynerba Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Zynerba Pharmaceuticals' history and understand the potential risks before investing.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |